Medscape (4/4, Brauser) reports that in order “to improve and reinvigorate the development of treatments for psychiatric disorders, the National Institute of Mental Health (NIMH) has made several changes to its funding policies for future clinical trials, according to a recent article (4/4) and a series of announcements published on the organization’s Web site.” Changes to the funding policies “include requiring that all new trials meet new efficiency, transparency, and reporting standards and that they must now examine possible mechanisms of action.”
American Psychiatric Association president Jeffrey Lieberman, MD, told Medscape Medical News that “he is particularly pleased with the NIMH’s commitment to having all new trials examine mechanisms.” Dr. Lieberman stated, “I think that model is a powerful and important one to emphasize.”
Related Links:
— Medscape (requires login and subscription)